drugset / Trial / NCT03480230
Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Phase 2
Unknown
60 enrolled
Arafat Tfayli
Merck KGaA, Darmstadt, Germany · collabPhoenix Clinical Research · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
Timeline
- Start
- 2018-06-26
- Primary completion
- 2022-11
- Completion
- 2022-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Compound 121564 | Unknown | 10 mg/kg | Intravenous |